Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns  

作　　者：Yi Dong Yi Sui Xin Cheng David Z Wang 

机构地区：[1]Department of Neurology,Huashan Hospital Fudan University,Shanghai,China [2]Department of Neurology,Shenyang Brain Hospital,Shenyang Medical College,Shenyang,China [3]Department of Neurology,The First People's Hospital of Shenyang,Shenyang,China [4]Department of Neurology,Barrow Neurological Institute,Phoenix,Arizona,USA

出　　处：《Stroke & Vascular Neurology》2022年第1期1-5,共5页卒中与血管神经病学（英文）

摘　　要：Tenecteplase(TNKase,TNK-tPA or TNK)is a thrombolytic agent derived from the tissue plasminogen activator(tPA).It is a 527-amino acid glycoprotein developed by replacing three amino acids at the T,N and K positions of the glycoprotein structure of tPA under genetic recombinant technology.After replacing threonine 103 with asparagine,asparagine 117 with glutamine and a tetra-alanine at amino acids 296–299,TNK is about eightfold more potent in dissolving clot,80-fold higher resistance to plasminogen activator inhibitor-1 and 14-fold enhanced relative fibrin specificity,and with a longer half-life(20 min).1 Hence,TNK is administered as a single intravenous bolus.

关 键 词：TECHNOLOGY replace replacing 

分 类 号：R741[医药卫生—神经病学与精神病学] R96[医药卫生—临床医学]